Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human, Single Arm, Open-label, Phase 1 Dose-Escalation Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

NCT06256055 is registered in ClinicalTrials.gov with UTC Therapeutics Inc. as lead sponsor.

NCT NCT06256055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06256055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human, Single Arm, Open-label, Phase 1 Dose-Escalation Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
Lead sponsor
UTC Therapeutics Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
March 5, 2024
Completion date
April 30, 2025
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer, breast cancer female, colorectal cancer, malignant mesothelioma, ovary cancer, pancreatic cancer, rectal cancer